Genetic Analysis AS announced a collaboration with Comono AS to develop a digital business platform for microbiome testing for the consumer market. The digital platform is already in advanced development, and a Joint Venture ("JV") will be set up to complete the development and commercialize the consumer offering with an expected launch in second quarter 2024. This JV aims initially to target the Nordic consumer market through online sales.

By combining GA's validated testing platform and bacteria know-how with advanced software, GA enters a strategic move into the microbiome consumer testing market to deliver a unique and user-friendly testing service ideal for the consumer market. Comono has a proven track record of successfully developing digital solutions and companies, particularly in the health sector. In collaboration, GA will combine its microbiome testing expertise and extensive bacteria database with software to establish a platform dedicated to consumer microbiome testing, with a primary emphasis on gut health.

GA will provide its testing services to the JV from its service lab in Oslo. In return, the JV's initial focus is on reaching the Nordic consumer market through online Sales. The platform's digital adaptability positions it for seamless expansion into other markets, including Europe, the US, and the Asian market in the future.

This platform is designed to swiftly deliver precise, high-quality, and actionable results to consumers. By doing so, GA aims to set a new standard in consumer microbiome testing in an era of advancements in health insights. The formation of the Joint Venture is underway, and GA will acquire a 33% ownership by investing NOK 500,000.

Initially, both GA and Comono will collectively invest a total of NOK 1.5 million, ensuring funding up to the product launch. In 2024, the JV aims to secure additional capital by attracting new investors and obtaining contributions from existing shareholders.